|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, the 12 weeks of PCA administration remarkably improved the endothelium-dependent vasorelaxation induced by insulin and IGF-1 in aging hypertension through enhancing the PI3K⁻NOS⁻NO pathway.
|
30934575 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Increased adipose cell size, hepatic fat deposition, malondialdehyde (MDA) content and NEFA level, down-regulation of IRS1, IRS2, PI3K, Akt, p-Akt, Glut2 and PGC1ɑ expression concomitant with up-regulation of mTOR, GSK3β, TNF-ɑ, FOXO1, p-mTOR and p-p70S6K expression in the liver tissue, as well as hypertension and left ventricular diastolic dysfunction were observed in HFC-fed minipigs.
|
30686655 |
2019 |
|
Hypertensive disease
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Protective effect of Fisetin against angiotensin II-induced apoptosis by activation of IGF-IR-PI3K-Akt signaling in H9c2 cells and spontaneous hypertension rats.
|
30668312 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Two of the most common toxicities not seen with other PI3K inhibitors include hyperglycemia and hypertension, which primarily occur during infusion and resolve shortly thereafter, and likely relate to targeting the PI3K alpha isoform.
|
30584024 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
NLRC3 inhibits MCT-induced pulmonary hypertension in rats via attenuating PI3K activation.
|
30767203 |
2019 |
|
Hypertensive disease
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
These changes in the Ang II-induced hypertension were effectively prevented by gene silencing of PI3K in the RVLM.
|
28191736 |
2017 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The Multifaceted Roles of PI3Kγ in Hypertension, Vascular Biology, and Inflammation.
|
27834808 |
2016 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, a survey of the studies dissecting the role of PI3Kγ in pathological conditions that are typically induced by hypertension in its target organs provides a more complete picture of the high potential of this novel therapeutic approach for fighting hypertension and, at the same time, its target organ damage, independently of blood pressure-lowering effects.
|
22610309 |
2012 |
|
Hypertensive disease
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Emerging evidence indicates that PI3K levels change in response to cellular stimulation with insulin and nuclear receptor ligands, and during various physiological and pathological processes including differentiation, regeneration, hypertension and cancer.
|
19299143 |
2009 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The relative specificity of these events suggests that blocking PI3Kgamma function might turn out beneficial for diseases like inflammation, allergy, thrombosis, and major cardiovascular disorders like hypertension, thus offering a wide range of therapeutic opportunities.
|
16543958 |
2006 |